Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Alternext  >  Biocorp    ALCOR   FR0012788065

BIOCORP

(ALCOR)
  Report
Delayed Quote. Delayed Euronext Alternext - 05/22 11:25:58 am
16.2 EUR   --.--%
04/09BIOCORP : 2019 annual results
PU
04/09BIOCORP : 2019 Annual Results
BU
04/09BIOCORP : Annual results
CO
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

Biocorp : 2020 financial calendar

share with twitter share with LinkedIn share with facebook
share via e-mail
01/09/2020 | 03:03am EDT

Communiqué de Presse

BIOCORP: 2020 financial calendar

Issoire, France, January 9th, 2020, 08h00 am CET - BIOCORP (FR0012788065 - ALCOR / Eligible PEA PME), a French company specialized in the development and manufacturing of medical devices and smart drug delivery systems, updates its financial reporting schedule for

2020*:

Annonce

Date*

2019 full-year results

Thursday, April 9th, 2020

Before the market opening

Annual shareholders meeting

Friday, May 15th, 2020

2020 first-half results

Thursday, September 24th, 2020

After the market close

  • This schedule is indicative and subject to change.

À PROPOS DE BIOCORP

Recognized for its expertise in the development and manufacture of medical devices and delivery systems, BIOCORP has today acquired a leading position in the connected medical device market thanks to Mallya. This intelligent sensor for insulin injection pens allows reliable monitoring of injected doses and thus offers better compliance in the treatment of diabetics. Available for sale from 2020, Mallya spearheads BIOCORP's product portfolio of innovative connected solutions. The company has 54 employees.

BIOCORP is listed on Alternext since July 2015 (FR0012788065 - ALCOR). For more information, please visit www.biocorpsys.com

Follow us on Twitter @BIOCORPSystems

BIOCORP CONTACTS

Jacques Gardette

Éric Dessertenne

Sylvaine Dessard

Chairman of the Board

CEO

Marketing @ Communication Director

investisseurs@biocorp.fr

rp@biocorp.fr

+ 33 (0)6 88 69 72 85

ULYSSE COMMUNICATION CONTACTS

Bruno ARABIAN

Nicolas DANIELS

barabian@ulysse-communication.com

ndaniels@ulysse-communication.com

+33 (0)6 87 88 46 26

+33 (0)6 63 66 59 22

Disclaimer

Biocorp Production SA published this content on 09 January 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 09 January 2020 08:02:00 UTC

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on BIOCORP
04/09BIOCORP : 2019 annual results
PU
04/09BIOCORP : 2019 Annual Results
BU
04/09BIOCORP : Annual results
CO
04/06BIOCORP : annual earnings release
02/19BIOCORP : Marketing partnership on Mallya with iSage Rx in the field of digital ..
PU
02/19BIOCORP : Marketing Partnership on Mallya with iSage Rx in the Field of Digital ..
BU
02/12BIOCORP : Strong Revenue Growth In 2019
BU
01/14BIOCORP : and SANOFI Strengthen Their Partnership With Mallya Smart Sensors
BU
01/09BIOCORP : 2020 financial calendar
PU
01/09BIOCORP : 2020 Financial Calendar
BU
More news
Financials (EUR)
Sales 2019 -
EBIT 2019 -
Net income 2019 -
Debt 2019 -
Yield 2019 -
P/E ratio 2019 -
P/E ratio 2020 108x
Capi. / Sales2019 -
Capi. / Sales2020 6,49x
Capitalization 66,9 M
Chart BIOCORP
Duration : Period :
Biocorp Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOCORP
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
 
Mean consensus -
Number of Analysts 1
Average target price 25,00 €
Last Close Price 16,20 €
Spread / Highest target 54,3%
Spread / Average Target 54,3%
Spread / Lowest Target 54,3%
EPS Revisions
Managers
NameTitle
Eric Dessertenne Chief Executive Officer
Jacques Gardette Chairman
Stéphane Chabanais Chief Financial & Administrative Officer
Alain Marcoz Director-Software Research & Development
Emilie Gardette Director
Sector and Competitors
1st jan.Capitalization (M$)
BIOCORP25.58%73
JOHNSON & JOHNSON-1.03%380 356
ROCHE HOLDING AG10.48%303 907
PFIZER, INC.-4.29%208 306
MERCK & CO., INC.-16.03%192 766
NOVARTIS AG-10.58%186 299